EUVIMEDEUVIMED entdecken
Crossref

Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features

Elżbieta Patkowska, Monika Prochorec-Sobieszek, Ewa Lech-Marańda, Barbara Nasiłowska-Adamska

Hematology in Clinical Practice · 2022

DOI: 10.5603/hcp.2022.0004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2022. Verfasst von Elżbieta Patkowska und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Patkowska, E., Prochorec-Sobieszek, M., Lech-Marańda, E., & Nasiłowska-Adamska, B. (2022). Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2022.0004

Vancouver

Patkowska E, Prochorec-Sobieszek M, Lech-Marańda E, Nasiłowska-Adamska B. Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features. Hematology in Clinical Practice. 2022. doi:10.5603/hcp.2022.0004

BibTeX
@article{Patkowska2022,
  author = {Patkowska, Elżbieta and Prochorec-Sobieszek, Monika and Lech-Marańda, Ewa and Nasiłowska-Adamska, Barbara},
  title = {Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features},
  journal = {Hematology in Clinical Practice},
  year = {2022},
  doi = {10.5603/hcp.2022.0004}
}
Kostenlos starten →